Shayegan Bobby, Pouliot Frédéric, So Alan, Fernandes John, Macri Joseph
Division of Urology, Department of Surgery, McMaster University, Hamilton, ON.
Division of Urology, Department of Surgery, Université Laval, Quebec, QC.
Can Urol Assoc J. 2017 Jun;11(6):204-209. doi: 10.5489/cuaj.4539.
Androgen-deprivation therapy (ADT) is a standard of care in the treatment of advanced prostate cancer; however, testosterone monitoring practices for men undergoing ADT vary across Canada. Although a testosterone level of 1.7 nmol/L or lower has historically been defined as the accepted castrate level, newer assays with improved sensitivity have shown that both medical and surgical castration can suppress testosterone levels to below 0.7 nmol/L. This review explores the evidence supporting a redefinition of the castrate testosterone level as 0.7 nmol/L or lower, and presents results of a survey of testosterone monitoring practices among 153 Canadian urologists, uro-oncologists, and radiation oncologists who manage the treatment of men with hormone-sensitive prostate cancer.
雄激素剥夺疗法（ADT）是晚期前列腺癌治疗的标准护理方法；然而，加拿大各地接受ADT治疗的男性的睾酮监测方法各不相同。虽然历史上一直将1.7 nmol/L或更低的睾酮水平定义为公认的去势水平，但灵敏度更高的新型检测方法表明，药物去势和手术去势都能将睾酮水平抑制至0.7 nmol/L以下。本综述探讨了支持将去势睾酮水平重新定义为0.7 nmol/L或更低的证据，并展示了一项针对153名治疗激素敏感性前列腺癌男性患者的加拿大泌尿科医生、泌尿肿瘤学家和放射肿瘤学家的睾酮监测方法调查结果。
